NRX Pharmaceuticals (NRXP) Research & Development (2020 - 2026)

NRX Pharmaceuticals (NRXP) has reported Research & Development for 7 consecutive years, with $2.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 114.39% year-over-year to $2.1 million in Q2 2026; TTM through Jun 2026 was $5.4 million, a 57.42% increase from a year earlier, with the FY2025 full-year figure at $3.8 million, down 39.07% from the prior year.
• Research & Development was $2.1 million for Q2 2026 at NRX Pharmaceuticals, up from $1.3 million in the prior quarter.
• Over five years, Research & Development peaked at $5.5 million in Q1 2022 and troughed at $558000.0 in Q4 2025.
• A 5-year average of $2.3 million and a median of $1.9 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development plunged 85.34% in 2023 and jumped 133.88% in 2025, its largest moves.
• Over 5 years, Research & Development stood at $4.5 million in 2022, then sank by 43.13% to $2.5 million in 2023, then sank by 59.12% to $1.0 million in 2024, then slumped by 46.14% to $558000.0 in 2025, then soared by 279.21% to $2.1 million in 2026.
• The last three Research & Development figures came in at $2.1 million (Q2 2026), $1.3 million (Q1 2026), and $558000.0 (Q4 2025), per Business Quant data.